Dr. John Ussher carried out his PhD training with Dr. Gary Lopaschuk at the University of Alberta (Sept 2004– Jan 2010), where he acquired expertise in the molecular regulation of cardiac energy metabolism, with a specific focus on pharmacologically increasing cardiac malonyl CoA content to treat ischemic heart disease. Following his PhD training, John trained with Dr. Daniel Drucker at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto (Mar 2010 – Oct 2014) to acquire extensive expertise in incretin hormone (e.g. glucagon-like peptide-1) biology and how incretin hormones influence the cardiovascular system. In November 2014, John returned to the University of Alberta with the Faculty of Pharmacy and Pharmaceutical Sciences, where his lab investigates the mechanisms by which obesity perturbs energy metabolism and contributes to the pathophysiology of insulin resistance, nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease (e.g. heart failure).
- To understand the physiological purpose for why the body produces ketone bodies
- To understand the alterations in muscle ketone body oxidation that take place during the pathology of obesity
- To understand how modifying muscle ketone body oxidation contributes to the regulation of glucose homeostasis in obesity/type 2 diabetes